Mitsubishi UFJ Asset Management Co. Ltd. decreased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 81.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,856 shares of the company's stock after selling 30,870 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.'s holdings in IDEAYA Biosciences were worth $178,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of IDEAYA Biosciences during the 4th quarter worth $35,000. Daiwa Securities Group Inc. increased its position in IDEAYA Biosciences by 44.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after purchasing an additional 853 shares in the last quarter. Quantbot Technologies LP bought a new position in IDEAYA Biosciences in the 3rd quarter valued at approximately $83,000. KBC Group NV lifted its stake in IDEAYA Biosciences by 84.6% in the 4th quarter. KBC Group NV now owns 4,197 shares of the company's stock valued at $108,000 after purchasing an additional 1,923 shares during the last quarter. Finally, Cibc World Markets Corp bought a new stake in shares of IDEAYA Biosciences during the fourth quarter worth $203,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.
IDEAYA Biosciences Stock Performance
Shares of NASDAQ IDYA traded down $0.64 during midday trading on Tuesday, reaching $14.50. The stock had a trading volume of 2,349,283 shares, compared to its average volume of 902,070. The company's 50 day moving average price is $19.50 and its 200 day moving average price is $24.69. IDEAYA Biosciences, Inc. has a twelve month low of $13.80 and a twelve month high of $44.42. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -4.39 and a beta of 0.51.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million. Equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.
Analysts Set New Price Targets
IDYA has been the subject of a number of research reports. Stephens reiterated an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Wedbush reiterated an "outperform" rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Royal Bank of Canada restated an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $53.58.
Get Our Latest Research Report on IDYA
IDEAYA Biosciences Company Profile
(
Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Featured Articles
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
